Complete leukaemia remissions credited to CAR T-cell persistence
The same immunological principle at the heart of vaccinations apply to CAR T-cells also, according to researchers
Two patients with chronic lymphocytic leukaemia have achieved 10-year remissions after treatment with chimeric antigen receptor T-cells, a ground-breaking report shows.
The US researchers say such a level of persistence and duration had not previously been observed with the ‘living’ anti-cancer therapy.
